The Role of P53 in Progression of Cutaneous Squamous Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 28

PMID 34572732

Citations 25

Authors

Minna Piipponen

Pilvi Riihila

Liisa Nissinen

Veli-Matti Kahari

Affiliations

Soon will be listed here.

Abstract

Skin cancers are the most common types of cancer worldwide, and their incidence is increasing. Melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC) are the three major types of skin cancer. Melanoma originates from melanocytes, whereas BCC and cSCC originate from epidermal keratinocytes and are therefore called keratinocyte carcinomas. Chronic exposure to ultraviolet radiation (UVR) is a common risk factor for skin cancers, but they differ with respect to oncogenic mutational profiles and alterations in cellular signaling pathways. cSCC is the most common metastatic skin cancer, and it is associated with poor prognosis in the advanced stage. An important early event in cSCC development is mutation of the gene and inactivation of the tumor suppressor function of the tumor protein 53 gene (TP53) in epidermal keratinocytes, which then leads to accumulation of additional oncogenic mutations. Additional genomic and proteomic alterations are required for the progression of premalignant lesion, actinic keratosis, to invasive and metastatic cSCC. Recently, the role of p53 in the invasion of cSCC has also been elucidated. In this review, the role of p53 in the progression of cSCC and as potential new therapeutic target for cSCC will be discussed.

Citing Articles

Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk.

Colegrove H, Monnat R, Monnat Jr R, Feder A bioRxiv. 2025; .

PMID: 40060430 PMC: 11888451. DOI: 10.1101/2025.02.26.640284.

From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments.

Li Z, Lu F, Zhou F, Song D, Chang L, Liu W Front Immunol. 2025; 16:1518633.

PMID: 39925808 PMC: 11802505. DOI: 10.3389/fimmu.2025.1518633.

Comparative Study of Cutaneous Squamous Cell Carcinogenesis in Different Hairless Murine Models.

Gkikas G, Katsiris D, Vitsos A, Gioran A, Ieronymaki D, Kostaki M Cancers (Basel). 2024; 16(20).

PMID: 39456640 PMC: 11506169. DOI: 10.3390/cancers16203546.

A new potential strategy for cutaneous squamous cell carcinoma treatment by generating serum-based antibodies from tumor-exposed mice.

Liu Z Elife. 2024; 13.

PMID: 39405093 PMC: 11479585. DOI: 10.7554/eLife.95678.

The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review.

Hosseini T, Park S, Guo T Cancers (Basel). 2024; 16(16).

PMID: 39199674 PMC: 11352924. DOI: 10.3390/cancers16162904.

References

Willis A, Jung E, Wakefield T, Chen X . Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004; 23(13):2330-8. DOI: 10.1038/sj.onc.1207396. View

Savar A, Acin S, Gonzalez C, El-Sawy T, Mejia O, Li Z . Loss of epithelial p53 and αv integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment. Oncogene. 2014; 34(4):516-24. PMC: 4303549. DOI: 10.1038/onc.2013.585. View

Li Y, Hanna G, Laga A, Haddad R, Lorch J, Hammerman P . Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015; 21(6):1447-56. PMC: 4359951. DOI: 10.1158/1078-0432.CCR-14-1773. View

Harwood C, Mesher D, McGregor J, Mitchell L, Leedham-Green M, Raftery M . A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant. 2012; 13(1):119-29. DOI: 10.1111/j.1600-6143.2012.04292.x. View

Torchia E, Caulin C, Acin S, Terzian T, Kubick B, Box N . Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene. 2011; 31(21):2680-90. PMC: 4576849. DOI: 10.1038/onc.2011.441. View

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh A . p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A. 2014; 111(32):E3287-96. PMC: 4136628. DOI: 10.1073/pnas.1321640111. View

Rowe D, Carroll R, Day Jr C . Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992; 26(6):976-90. DOI: 10.1016/0190-9622(92)70144-5. View

Taguchi M, Watanabe S, Yashima K, Murakami Y, Sekiya T, Ikeda S . Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. J Invest Dermatol. 1994; 103(4):500-3. DOI: 10.1111/1523-1747.ep12395643. View

10.

Chitsazzadeh V, Coarfa C, Drummond J, Nguyen T, Joseph A, Chilukuri S . Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016; 7:12601. PMC: 5013636. DOI: 10.1038/ncomms12601. View

11.

Botchkarev V, Flores E . p53/p63/p73 in the epidermis in health and disease. Cold Spring Harb Perspect Med. 2014; 4(8). PMC: 4109579. DOI: 10.1101/cshperspect.a015248. View

12.

Vieler M, Sanyal S . p53 Isoforms and Their Implications in Cancer. Cancers (Basel). 2018; 10(9). PMC: 6162399. DOI: 10.3390/cancers10090288. View

13.

Mueller S, Gauthier M, Ashford B, Gupta R, Gayevskiy V, Chng S . Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma. J Invest Dermatol. 2019; 139(7):1449-1458.e1. DOI: 10.1016/j.jid.2019.01.008. View

14.

Manyam B, Garsa A, Chin R, Reddy C, Gastman B, Thorstad W . A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017; 123(11):2054-2060. DOI: 10.1002/cncr.30601. View

15.

Liu Y, Tavana O, Gu W . p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019; 11(7):564-577. PMC: 6736412. DOI: 10.1093/jmcb/mjz060. View

16.

Kramata P, Lu Y, Lou Y, Singh R, Kwon S, Conney A . Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB Irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. Cancer Res. 2005; 65(9):3577-85. DOI: 10.1158/0008-5472.CAN-04-4537. View

17.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

18.

Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I . Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 2007; 21(5):562-77. PMC: 1820898. DOI: 10.1101/gad.1484707. View

19.

Feng C, Zhang H, Zeng A, Bai M, Wang X . Tumor-Suppressive MicroRNA-216b Binds to TPX2, Activating the p53 Signaling in Human Cutaneous Squamous Cell Carcinoma. Mol Ther Nucleic Acids. 2020; 20:186-195. PMC: 7068200. DOI: 10.1016/j.omtn.2020.01.022. View

20.

Martins V, Caley M, Moore K, Szentpetery Z, Marsh S, Murrell D . Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC. J Natl Cancer Inst. 2015; 108(1). DOI: 10.1093/jnci/djv293. View